Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 October 2026, is structured as an asset sale within the healthcare sector. Both the buyer and the target are based in the United States. The consideration for this acquisition consists of cash payments alongside an earn-out component. This arrangement allows for part of the total value to be contingent on future performance metrics, although specific details regarding the earn-out conditions are not provided in the available data. The transaction represents a significant move for Laboratory Corporation of America Holdings, expanding its portfolio through the purchase of assets from BioReference Health, LLC.

The current status of the deal is recorded as firm intention, indicating that the parties have reached a definitive agreement. No completion date has been reported, and the transaction remains pending finalisation. Regulatory approvals and other customary closing conditions may still need to be satisfied before the transfer of assets is complete. This summary reflects the known facts as of the announcement date, without speculation on strategic motivations or comparative market analysis. The focus remains on the structural elements and the reported financial terms of the agreement between the two US-based entities.